Alexander Stein

Alexander Stein

Auto-generated profile, based on publicly available information

Alexander Stein

Hematology-Oncology Practice Eppendorf (HOPE) and University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAlexander Stein
Alexander Stein
DADirk Arnold
Dirk Arnold
JBJohn Bridgewater
John Bridgewater
DGDavid Goldstein
David Goldstein
LJLars Henrik Jensen
Lars Henrik Jensen
HWHenning Wege
Henning Wege
Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more than 35 % after three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis is even worse, with an overall survival (OS) of only 30 % after three years. Thus, evaluation of adjuvant chemotherapy in biliary tract cancer in a large randomized trial is warranted. ACTICCA-1 is a randomized, multidisciplinary, multinational phase III investigator initiated trial. With respect to data obtained in the ABC-02 trial, we selected the combination of gemcitabine and cisplatin for 24 weeks as investigational treatment. Based on adjuvant trials in pancreatic cancer with comparable postoperative recovery time, inclusion of patients within a maximum interval of 16 weeks between surgery and start of chemotherapy was stipulated. Due to the different prognosis and treatment susceptibility of muscle invasive carcinoma, two separate cohorts (CCA and GBCA) were included to capture the potentially different treatment effects. Randomization is stratified for lymph node status for both cohorts and localization for CCA. The primary endpoint is DFS and secondary endpoints include OS, safety and tolerability of chemotherapy, quality of life, and patterns of disease recurrence. For CCA, adjuvant chemotherapy should increase DFS 24 months post-surgery from 40 to 55 % to be considered relevant. With a power of 80 % and a significance level of 5 %, 271 evaluable study patients have to be followed for 24–28 months to observe 166 events. For GBCA, chemotherapy should increase DFS 24 months post-surgery from 35 to 55 % to be of relevance; thus, 154 evaluable study patients have to be monitored for 24–28 months to observe 90 events. In both cohorts, randomization will be 1:1 with chemotherapy for 24 weeks and imaging every twelve weeks. In 2014, the study was initiated in Germany and in The Netherlands (funded by the Deutsche Krebshilfe, the Dutch Cancer Society, and supported by medac GmbH). Sites in Australia, Denmark, and the United Kingdom (funded by Cancer Research UK) are joining 2015. The study is registered with ClinicalTrials.gov ( NCT02170090 ) and the European Clinical Trials Database (2012-005078-70). Registration date is 06/18/2014.

1 January 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Hans Joachim SchmollHans Joachim Schmoll
Hans Joachim Schmoll
ASAlexander Stein
Alexander Stein
ECEric Van Cutsem
Eric Van Cutsem
TPTimothy Price
Timothy Price
RHRalf D. Hofheinz
Ralf D. Hofheinz
KHKarin Haustermans
Karin Haustermans
PURPOSE: The PETACC 6 trial investigates whether the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal cancer. METHODS: Between November 2008 and September 2011, patients with rectal adenocarcinoma within 12 cm from the anal verge, T3/4 and/or node positive, were randomly assigned to 5 weeks preoperative capecitabine-based chemoradiation (45-50.4 Gy) followed by six cycles of adjuvant capecitabine, both without (control arm, 1) or with (experimental arm, 2) oxaliplatin. The primary end point was improvement of 3-year DFS by oxaliplatin from 65% to 72% (hazard ratio [HR], 0.763). RESULTS: A total of 1,094 patients were randomly assigned (intention to treat), and 1,068 eligible patients started their allocated treatment (arm 1, 543; arm 2, 525), with completion of protocol treatment in 68% (arm 1) v 54% (arm 2). A higher rate of grade 3/4 adverse events was reported in the experimental arm (14.4% v 37.3% and 23.4% v 46.6% for neoadjuvant and adjuvant treatment, respectively). At a median follow-up of 68 months (interquartile range, 58-74 months), 157 and 156 DFS events were observed in arms 1 and 2, respectively (adjusted HR, 1.02; 95% CI, 0.82 to 1.28; P = .835). Three-year DFS rate was not different, with 76.5% (95% CI, 72.7% to 79.9%) in arm 1, which is higher than anticipated, and 75.8% (95% CI, 71.9% to 79.3%) in arm 2. The 7-year DFS and overall survival (OS) rates were not different as well, with DFS of 66.1% v 65.5% (HR, 1.02) and OS of 73.5% v 73.7% (HR, 1.19) in arms 1 and 2, respectively. Subgroup analyses revealed heterogeneity in treatment effect according to German versus non-German site location, without detectable confounding factors in multivariable analysis. CONCLUSION: The addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative adjuvant chemotherapy impairs tolerability and feasibility and does not improve efficacy.

9 December 2011 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
ASAlexander Stein
Alexander Stein
DADirk Arnold
Dirk Arnold
Oxaliplatin, a second-generation platinum analog, has evolved as one of the most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major impact on the management and outcome of this disease. The pharmacokinetic and pharmacodynamic data of oxaliplatin are reviewed in this paper. It also discusses the current clinical data regarding the use of oxaliplatin in early colon cancer, locally advanced rectal cancer, and in the metastatic setting, with a particular reference to its combination with monoclonal antibodies, and strategies for prevention of cumulative toxicity. Oxaliplatin has proven beneficial in the treatment of CRC and can currently be regarded as one of the three most important chemotherapeutic drugs used in the treatment of both metastatic disease and adjuvant therapy in stage II/III after resection. With regards to a median overall survival of more than 20 months, and a median progression-free survival for first-line treatment of about 9 - 10 months, the majority of patients will receive all three compounds (oxaliplatin, fluoropyrimidines and irinotecan) during the course of their disease. At the moment there are no drugs in late clinical development which might be able to substitute oxaliplatin in its unique role in CRC.

20 October 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Viktor GruenwaldViktor Gruenwald
Viktor Gruenwald
AKAnnika Karch
Annika Karch
MSMarkus Schuler
Markus Schuler
PSPatrick Schöffski
Patrick Schöffski
HKHans-Georg Kopp
Hans-Georg Kopp
AKAnnegret Kunitz
Annegret Kunitz
PURPOSE: Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity. PATIENTS AND METHODS: Patients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles) after being randomly assigned in a 2:1 ratio. Noninferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% CI for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary end points. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient-reported outcomes. Cox regression analysis and Kaplan-Meier curves were used for analysis. RESULTS: Pazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. Overall survival did not differ significantly between arms (HR, 1.08; 95% CI, 0.68 to 1.72; P = .735). Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients. CONCLUSION: Pazopanib was noninferior to doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. The distinct adverse event profile may be used to counsel patients and tailor therapy to individual needs.

23 June 2022 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ASAlexander Stein
Alexander Stein
LPLisa Paschold
Lisa Paschold
JTJoseph Tintelnot
Joseph Tintelnot
EGEray Goekkurt
Eray Goekkurt
SHSvenja-Sibylla Henkes
Svenja-Sibylla Henkes
MBMascha Binder
Mascha Binder
Globally, 1.7 million new cases of gastric and esophageal cancer occur each year.1 With more than 1.3 million deaths per year, these cancers remain among the leading causes of cancer-related mortality worldwide.1 Recurrent or metastatic disease affects about 75% of patients with esophagogastric adenocarcinomas (EGAs) at some point. For these patients, palliative systemic therapy remains the mainstay of treatment.

7 August 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JTJoseph Tintelnot
Joseph Tintelnot
ASAlexander Stein
Alexander Stein
In contrast to other tumor types, immunotherapy has not yet become a relevant part of the treatment landscape of unselected colorectal cancer. Beside the small subgroup of deficient mismatch repair or microsatellite instable tumors (about 5%) as a surrogate for high mutational burden and subsequently high neoantigen load and immunogenicity, inhibitors of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and/or cytotoxic T lymphocyte-associated antigen-4 were not or only modestly effective in metastatic colorectal cancer. Thus, a variety of combination approaches with chemotherapy, targeted therapy, toll-like receptor agonists, local ablation or oncolytic viruses is currently being evaluated in different disease settings. Despite several encouraging single arm data already presented or published, available randomized data are unimpressive. Adding PD-1/PD-L1 inhibitors to fluoropyrimidines and bevacizumab maintenance showed no beneficial impact on delaying progression. In refractory disease, the combination of PD-1/PD-L1 and MEK inhibitor was not different from regorafenib, whereas a PD-1/PD-L1 and cytotoxic T lymphocyte-associated antigen-4 inhibitor combination demonstrated better overall survival compared to supportive care alone. Clinical trials in all disease settings applying different combination approaches are ongoing and may define the role of immunotherapy in colorectal cancer.